期刊文献+

乳腺癌MRI表现与其分子分型的相关分析 被引量:3

下载PDF
导出
摘要 目的探讨不同分子分型乳腺癌的磁共振(MRI)影像学表现特点及各分子分型与MRI征象之间的相关性。方法收集60例行乳腺MRI扫描的乳腺癌患者的影像资料,分析乳腺癌MRI表现,术后乳腺癌组织标本行免疫组织化学染色确定其分子分型,并分析各分子分型与MRI征象相关性。结果 luminal-A型乳腺癌MRI多表现为形态不规则肿块样病变,边缘常有毛刺,边界模糊(P=0.006);luminal-B型乳腺癌MRI多表现为形态不规则肿块样病变,强化多不均匀,边缘可有毛刺(P=0.004);Her2乳腺癌MRI多表现为非肿块样病变或形态较规则肿块,病变范围较大,边缘较光滑,多为肿瘤周边强化(P=0.005);三阴性乳腺癌MRI多表现为肿瘤边缘较光滑,多呈环状强化,肿瘤内多出现液化坏死信号(P=0.007)。结论乳腺癌的MRI表现与其不同分子分型之间存在一定的相关性,对从影像学角度分析乳腺癌的分子分型有一定的参考价值。
出处 《山东医药》 CAS 北大核心 2015年第9期50-51,共2页 Shandong Medical Journal
  • 相关文献

参考文献1

二级参考文献11

  • 1汪晓红,耿道颖,顾雅佳,彭卫军,杨天锡.动态增强MRI鉴别乳腺良恶性病变的价值[J].放射学实践,2005,20(8):662-666. 被引量:58
  • 2Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits ofhuman breast tumours. Nature, 2000, 406 :747-752.
  • 3Wolff AC, Hammond ME, Schwartz JN , et al. American Societyof Clinical Oncology/College of American Pathologists guidelinerecommendationa for human epidermal growth factor receptor 2testing in breast cancer. Arch Pathol Lab Med, 2007, 131 :18-43.
  • 4Onililo AA, Engel JM, Greenlee RT, et al. Breast cancersubtypes based on ER/PR and Her2 expression: comparison ofdinicopathologic features and survival. Clin Med Res, 2GC9, 7:4-13.
  • 5Kobayashi M, Kawashima H,Matsui 0, et al. Two difft*rent typesof ring-like enhancement cm dynamic MR imaging in breastcancer : correlation with the histopathologic findings. J Magn ResonImaging, 2008, 28 : 1435-1443.
  • 6Laml) PM, Perry NM, Vinnicombe SJ, et al. Correlation betweenultrasound characteristics, mammographic findings and histologicalgrade in patients with invasive ductal carcinoma of the breast. ClinRadiol, 2000,55:4044.
  • 7Cooke T, Reeves J, Kannigan A , et al. The value of the humanepidermal growth factor receptor-2 ( HER2 ) as a prognosticmarker. Eur J Cancer, 2001,37 Suppl 1 :3-10.
  • 8Mossa-Basha M , Fundaro GM , Shah BA, et a). Ductal carcinomain situ of the breast: MR imaging findings with histopathologiccorrelation. Radiographics, 2010 , 30 : 1673-1687.
  • 9Cleator S, Heller W, Coombes RC. Triple-negative breast cancer:therapeutic options. Lancet Oncol, 2007,8 : 235-244.
  • 10Kang SP, Martel M, Harris LN. Triple negative breast cancer:current understanding of l)iology and treatment options. Curr OpinObstet Gynecol, 2008,20 : 40-46.

共引文献25

同被引文献25

  • 1周才明,黎绍基,何健标.乳腺癌淋巴结转移与ER,PR,Ki67,p53表达的相关分析及临床意义[J].广东医学,2007,28(4):510-512. 被引量:12
  • 2Jemal A,Bray F,Center MM, et al. Global cancer statistics. CA CancerJ Clin,2011,61(2):69-90.
  • 3Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes-dealing with the diversity of breast cancer : highlights of the St.GallenInternational Expert Consensus on the primary Therapy of Early BredstCancer 2011 [J].Ann Oncol, 2011,22( 8 ) : 1736-1747.
  • 4Cheang MC,Chia SK,Voduc D,et al.Ki-67 index,HER2 status,andprognosis with luminal B breast cancer [J]J Natl cancer Inst,2009,101(10):736-750.
  • 5Hammond ME,Hayes DF,Dowsett M,et al,American Society ofClinical Oncology/College of American Pathologists guidelinerecommendations for immunohistochemical testing of estrogen andprogesterone receptors in breast cancer [J].Arch Pathol Lab Med,2010,134(6):907-922.
  • 6American College of Radiology (ACR),Breast imaging reporting anddate system (BI-RADS),3rd edition [J], American College ofRadiology, 1998,36(2):588-590.
  • 7Jinno H, Matsuda S, Hayashida T,ef al.Differential pathologicalresponse to preoperative chemotherapy across breast cancer intrinsicsubtypes[J].Chemotherapy,2012,58(5) : 364-370.
  • 8Grunt TW,Mariani GLNovel approaches for molecular targeted therapyof breast cancer : Interfering with P13K/AKT/mT0R signaling [J].Current Cancer Drug Targets,2013,13(6) : 188-204.
  • 9刁岩,任宏涛,王西京,马小斌,代志军.PCNA,MMP-2在PR阳性的乳腺癌组织中的表达及意义[J].当代医学,2011,17(32):39-40. 被引量:1
  • 10水若鸿,杨文涛,龚西騟.腔面型乳腺癌的临床病理特征和研究进展[J].临床与实验病理学杂志,2013,29(3):235-239. 被引量:10

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部